** Life sciences firm Danaher DHR.N raised its annual profit forecast on Tuesday, banking on steady demand for bioprocessing from its pharmaceutical clients and a recovery in China
BIOPROCESSING GROWTH IN FOCUS
** J.P.Morgan ("overweight," PT: $260) says DHR remains a top pick given its strong product portfolio that is shielded from macro pressures
** Wells Fargo ("equal weight," PT: $205) says bioprocess continues to show solid recovery while the life sciences segment is set to improve in the second half of the year
** Barclays ("overweight," PT: $225) sees 5-6% core growth for the business in 2026 if demand for bioprocessing picks up
** Raymond James ("market perform") expects 8-9% growth in Q4 given commercial exposure and supporting order book
(Reporting by Kanchana Chakravarty in Bengaluru)
((Kanchana.Chakravarty@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.